Pricing and reimbursement in Poland – problems and progress.
The introduction of the Reimbursement Act in Poland in 2012 brought a number of significant changes in the Polish pharmaceutical market place. Initially trends following the new Act were received negatively by the industry. However, two years on, opportunity is rising in the region both for generic players due to the country’s universal insurance coverage, and for innovative new medicines following the adoption of Risk Sharing Agreements and bids by government to speed up appraisal processes.
Below is a snapshot of the pitfalls affecting – and the promise offered to –new drugs entering the market in Poland. For more information on pricing and reimbursement in the country check out a new white paper on the topic, click here